11,424 Shares in Perspective Therapeutics, Inc. (NYSE:CATX) Purchased by Los Angeles Capital Management LLC

Los Angeles Capital Management LLC acquired a new stake in shares of Perspective Therapeutics, Inc. (NYSE:CATX) in the third quarter, Holdings Channel.com reports. The firm acquired 11,424 shares of the company’s stock, valued at approximately $153,000.

Other institutional investors and hedge funds have also modified their holdings of the company. Vanguard Group Inc. grew its position in Perspective Therapeutics by 34.6% during the first quarter. Vanguard Group Inc. now owns 17,780,106 shares of the company’s stock valued at $21,158,000 after buying an additional 4,566,356 shares during the period. Janus Henderson Group PLC acquired a new stake in Perspective Therapeutics in the 1st quarter valued at $15,511,000. Affinity Asset Advisors LLC purchased a new stake in shares of Perspective Therapeutics during the first quarter worth about $6,069,000. Nicholson Wealth Management Group LLC acquired a new position in shares of Perspective Therapeutics during the 3rd quarter worth about $21,390,000. Finally, Hills Bank & Trust Co purchased a new position in Perspective Therapeutics in the 3rd quarter valued at about $13,722,000. Institutional investors and hedge funds own 54.66% of the company’s stock.

Perspective Therapeutics Price Performance

Perspective Therapeutics stock opened at $6.95 on Tuesday. The company has a 50 day moving average price of $12.55. Perspective Therapeutics, Inc. has a 1-year low of $2.28 and a 1-year high of $19.05.

Perspective Therapeutics (NYSE:CATX) last posted its earnings results on Tuesday, November 12th. The company reported ($0.21) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.21). Perspective Therapeutics had a negative return on equity of 27.40% and a negative net margin of 4,096.66%. The company had revenue of $0.37 million during the quarter. As a group, equities analysts forecast that Perspective Therapeutics, Inc. will post -0.86 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

CATX has been the subject of several research reports. UBS Group started coverage on Perspective Therapeutics in a research note on Thursday, October 24th. They set a “buy” rating and a $20.00 price objective for the company. Cantor Fitzgerald reissued an “overweight” rating on shares of Perspective Therapeutics in a research note on Monday, September 9th. Truist Financial began coverage on shares of Perspective Therapeutics in a research note on Wednesday, September 25th. They set a “buy” rating and a $21.00 target price on the stock. Bank of America began coverage on shares of Perspective Therapeutics in a research report on Thursday, July 25th. They issued a “buy” rating and a $24.00 target price for the company. Finally, Wedbush restated an “outperform” rating and set a $20.00 price target on shares of Perspective Therapeutics in a research report on Thursday, October 24th. Nine analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $21.57.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.